MARKET

MTVA

MTVA

MetaVia Inc
NASDAQ
1.740
-0.270
-13.43%
Pre Market: 1.657 -0.083 -4.76% 04:49 06/15 EDT
OPEN
1.880
PREV CLOSE
2.010
HIGH
2.170
LOW
1.720
VOLUME
6.53K
TURNOVER
0
52 WEEK HIGH
19.03
52 WEEK LOW
0.9661
MARKET CAP
8.99M
P/E (TTM)
-0.2887
1D
5D
1M
3M
1Y
5Y
1D
MetaVia: Buy Rating Reiterated as Synergistic Cardiometabolic Pipeline Supports Unchanged $8 Price Target
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: MetaVia (MTVA) and Adlai Nortye Ltd. Sponsored ADR (ANL)
TipRanks · 5d ago
Pre-Market Movers: RGNT, FEED, BYAH Swing Big
NASDAQ · 5d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 5d ago
BIOSTEM TECHNOLOGIES ANNOUNCES APPOINTMENT OF THREE NEW MEMBERS TO ITS BOARD OF DIRECTORS
Reuters · 5d ago
Why Nuvalent Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Benzinga · 5d ago
MetaVia Shareholders Approve Equity Plan and Reverse Split
TipRanks · 6d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 6d ago
More
About MTVA
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.

Webull offers MetaVia Inc stock information, including NASDAQ: MTVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MTVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MTVA stock methods without spending real money on the virtual paper trading platform.